文献速递细菌感染、耐药与抗菌药物医院感染防控

如何加速抗菌药物敏感性试验

How to accelerate antimicrobial susceptibility testing.
PubMed 文献 · Clin Microbiol Infect · 2019-05-02

本文综述了加速抗菌药物敏感性试验(rAST)的现状,指出表型rAST通用但耗时,耐药机制检测快速但临床解释有限;MALDI-TOF MS-based AST与鉴定结合最具前景,直接检测以阳性血培养最适宜,多微生物样本和接种物效应是障碍;技术与流程优化可使AST报告在同一工作班次内完成,但广泛推广需低成本易用技术。

要点

  • 表型rAST通用但需等待菌株生长及耐药表达,机制检测快但临床解释受限。
  • MALDI-TOF MS-based AST可与鉴定优化组合,阳性血培养最适合直接检测。
  • 多微生物样本和接种物效应是直接AST的主要障碍,需优化前分析与实验室组织。

核心结论

  • 在同一工作班次内生成AST报告是可行的,但仅经济且易用的rAST技术才有机会进入广泛诊断常规。

研究设计与样本

  • 本文为综述,检索了rAST方法及其在常规诊断中实施的文献。

主要发现

  • 表型rAST通用、机制无关且可精确分类,但需时间让微生物开始生长并表达对 antibiotics 的应答。
  • 检测特定耐药机制更快速,但其临床影响的解释有限。
  • MALDI-TOF MS-based AST似乎特别有前景,因其可与MALDI-TOF MS鉴定最优组合。
  • 直接检测临床标本可提供特别早期的结果,阳性血培养是最适宜的标本类型。
  • 多微生物样本和接种物效应是从其他临床标本直接AST的严重障碍。

关键数值与推荐

  • 成功的rAST assay标准包括易用、随机访问、可同时检测多个标本、可负担及对产业有财务吸引力。
  • 表型rAST的技术挑战包括接种物效应、耐药延迟表达、滞后期和敏感分离株初始生物量增加。

临床怎么用

  • 微生物学家和临床医生可参考本文了解加速AST的当前可能性及技术策略。
  • 优化前分析和实验室组织与技术进步同样重要,以支持同一工作班次内报告AST。

局限性

  • 原文未报告具体研究数量、样本量或统计数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial susceptibility testing (AST) results are crucial for timely administration of effective antimicrobial treatment, and, thus, should be made available to clinicians as fast as possible. In particular, increasing rates of multidrug-resistant organisms emphasize the need for rapid AST (rAST). OBJECTIVES: This article aims to provide microbiologists and clinicians with a critical overview of the current state of possibilities to accelerate AST. We also intend to discuss technical and strategic aspects of rAST, which may be helpful to academic researchers and assay developers in the industry. SOURCES: We have reviewed literature on rAST methods and their implementation in routine diagnostics. CONTENT: Phenotypic rAST is universal, mechanism-independent and allows exact categorization, but it demands time for the microorganisms to start the growth and to express the response to antibiotics. Detection of selected resistance mechanisms is more rapid, but the interpretation of its clinical impact is limited. Technical challenges of phenotypic rAST include inoculum effect, delayed expression of resistance, lag phase and initial biomass increase in susceptible isolates. Criteria for a successful rAST assay are ease of use, random access, capacity for simultaneous testing of multiple specimens, affordability and financial attractiveness for industry. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based AST seems to be particularly promising, as it can optimally be combined with MALDI-TOF MS identification. Direct testing from clinical specimens provides particularly early findings, with positive blood cultures being the most suitable specimen type. Polymicrobial samples and inoculum effect are serious obstacles for direct AST from other clinical specimens. Next to the technology improvement, optimization of pre-analytics and laboratory organization is essential. IMPLICATIONS: It appears feasible to generate an AST report within the same working shift; however, only affordable and easy-to-use rAST technologies have a chance to enter broad diagnostic routine. Efforts should be made by industry, authorities and academia to enable wide dissemination of rAST in clinical diagnostics.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Idelevich EA, Becker K. How to accelerate antimicrobial susceptibility testing. Clin Microbiol Infect. 2019. PMID: 31055166. doi:10.1016/j.cmi.2019.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。